Eris Lifesciences Completes Swiss Parenterals Acquisition Through Share Allotment
Eris Lifesciences successfully completed its strategic acquisition of Swiss Parenterals Limited on January 16, 2026, by allotting 23,06,372 equity shares at ₹1,835.35 per share through preferential allotment to Mr. Naishadh Shah. The non-cash transaction involved a share swap for the remaining 30% stake in Swiss Parenterals, making it a wholly-owned subsidiary and increasing Eris Lifesciences' paid-up capital to ₹13.85 crores.
*this image is generated using AI for illustrative purposes only.
Eris Lifesciences Limited has successfully completed its strategic acquisition of Swiss Parenterals Limited, transforming the subsidiary into a wholly-owned entity through a preferential share allotment completed on January 16, 2026. The pharmaceutical company's Executive Committee approved the allotment of equity shares in exchange for the remaining 30% stake in Swiss Parenterals.
Share Allotment Details
The Executive Committee of Eris Lifesciences' Board approved the allotment of significant equity shares to complete the acquisition:
| Parameter: | Details |
|---|---|
| Shares Allotted: | 23,06,372 equity shares |
| Face Value: | ₹1.00 per share |
| Issue Price: | ₹1,835.35 per share |
| Premium: | ₹1,834.35 per share |
| Allottee: | Mr. Naishadh Shah |
| Consideration: | Non-cash (share swap) |
The allotment was made on a preferential basis through private placement to Mr. Naishadh Shah in exchange for his 16,74,493 equity shares of Swiss Parenterals Limited, representing the remaining 30% stake in the subsidiary.
Capital Structure Impact
The share allotment has resulted in changes to Eris Lifesciences' capital structure:
| Metric: | Before Allotment | After Allotment |
|---|---|---|
| Paid-up Capital: | ₹13.62 crores | ₹13.85 crores |
| Total Equity Shares: | 13,62,16,891 | 13,85,23,263 |
| Face Value per Share: | ₹1.00 | ₹1.00 |
Regulatory Compliance and Approvals
The transaction was executed following comprehensive regulatory compliance. The company received in-principle approval from both NSE and BSE on January 9, 2026, for the preferential issue. The process began with the board meeting held on November 24, 2025, followed by shareholder approval through postal ballot on December 24, 2025.
The allotment complies with provisions of the Companies Act, 2013, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newly allotted shares will rank pari-passu with existing equity shares, subject to lock-in restrictions under SEBI ICDR Regulations.
Strategic Implications
With the completion of this acquisition, Swiss Parenterals Limited has become a wholly-owned subsidiary of Eris Lifesciences. This strategic move provides the company with enhanced control over Swiss Parenterals' operations and potential operational synergies. The subscription shares will be listed on NSE and BSE upon receipt of relevant listing approvals and will be subject to lock-in provisions as specified under Chapter V of the SEBI ICDR Regulations.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.07% | +0.26% | -15.25% | -17.36% | -28.17% | +40.37% |
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
